Compare PBF & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | INDV |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 2011 | 2014 |
| Metric | PBF | INDV |
|---|---|---|
| Price | $40.37 | $39.44 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $36.25 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 1.9M |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | 69.78 | ★ 8100.00 |
| EPS | ★ 1.65 | 0.69 |
| Revenue | ★ $24,508,200,000.00 | $1,239,000,000.00 |
| Revenue This Year | $8.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $24.55 | $57.28 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $17.53 | $11.07 |
| 52 Week High | $52.18 | $41.00 |
| Indicator | PBF | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 71.62 |
| Support Level | $27.35 | $29.71 |
| Resistance Level | $47.18 | N/A |
| Average True Range (ATR) | 2.41 | 1.53 |
| MACD | 0.01 | 0.61 |
| Stochastic Oscillator | 35.99 | 82.67 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).